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The CA 125 II assay on the Elecsys® 2010 analyzer was
evaluated in an international multicenter trial. Impreci-
sion studies yielded within-run CVs of 0.8–3.3% and
between-day CVs of 2.4–10.9%; CVs for total impreci-
sion in the manufacturer’s laboratory were 2.4–7.8%.
The linear range of the assay extended to at least 4500
kilounits/L (three decades). Interference from triglycer-
ides (10.3 mmol/L), bilirubin (850 mmol/L), hemoglobin
(1.1 mmol/L), anticoagulants (plasma), and several
widely used drugs was undetectable. Method compari-
sons with five other CA 125 II assays showed good
correlation but differences in standardization. A 95th
percentile cutoff value of 35 kilounits/L was calculated
from values measured in 593 apparently healthy (pre-
and postmenopausal) women. In 95% of patients with
benign gynecological diseases CA 125 was <190 kilo-
units/L; 63% of patients with newly diagnosed ovarian
carcinoma had values >190 kilounits/L. A comparison of
CA 125 values obtained with the Elecsys test and with
other common CA 125 tests in monitored patients being
treated for ovarian cancer showed identical patterns. In
conclusion, the Elecsys CA 125 II assay is linear over a
broad range, yields precise and accurate results, is free
from interferences, and compares well with other as-
says.
CA 125 is a glycoprotein that occurs in blood as high
molecular weight (Mr .200 000) aggregates. High concen-
trations are associated with ovarian cancer and with a
range of benign and malignant diseases. Although the
specificity and sensitivity of CA 125 assays are somewhat
limited, especially in the early diagnosis of ovarian can-
cer, the assay has found widespread use in the differential
diagnosis of adnexal masses, in monitoring disease pro-
gression and response to therapy in ovarian cancer, and in
the early detection of recurrence after surgery or chemo-
therapy for ovarian cancer. The use of CA 125 assays has
been reviewed excellently (1, 2). Most assays for the
determination of CA 125 use the M11 antibody for capture
and the OC125 antibody as tracer. Such assays are named
CA 125 II. Recently, Boehringer Mannheim GmbH intro-
duced a fully automated CA 125 II assay on their Elecsys®
2010 analyzer. This study describes the results of an
extensive multicenter, international evaluation of the an-
alytical and clinical performance of this assay.
Materials and Methods
test principle
The Elecsys CA 125 II test is a sandwich immunoassay
that is provided for Elecsys immunoassay systems (Boehr-
inger Mannheim GmbH). As described recently (3), these
instruments use electrochemiluminescence as the detec-
tion technology, thereby offering the advantage of short
reaction times and high sensitivity. A 40-mL sample is
incubated with biotinylated M11 capture antibody and
ruthenylated OC125 tracer antibody. After 9 min, strepta-
vidin-coated paramagnetic beads are added, followed by
an additional 9-min incubation period. The reaction mix-
ture is then drawn into the measuring cell where the
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following steps take place: capture of the magnetic beads,
addition of buffer containing tripropylamine, and voltage
application and measurement of the resulting electro-
chemiluminescence by a photomultiplier. Results are
available after 18 min.
The CA 125 test is calibrated against the Enzymun-
Test® CA 125 II (Boehringer Mannheim GmbH). Reagent-
specific application data and a master calibration curve
are stored on two-dimensional bar codes supplied with
the reagents. Two-point calibration in the user’s labora-
tory adapts the master calibration curve to the analyzer.
Reagents and calibrators are ready to use.
analytical evaluation of elecsys ca 125 ii
The test was evaluated according to a standardized pro-
tocol based on the concepts of a European Committee for
Clinical Laboratory Standards document (4) in eight clin-
ical laboratories on fully automated Elecsys 2010 systems.
Imprecision. Imprecision studies were carried out using
control materials and human pool sera with defined
concentration ranges of CA 125. Within-run imprecision
(CV; 21 replicates per analysis) was determined in seven
laboratories, and between-day imprecision (measurement
once daily for 21 days) was determined in five laborato-
ries. Total imprecision was measured in the laboratory of
the manufacturer following the NCCLS EP5-T protocol.
Accuracy. Five laboratories participated in a small inter-
laboratory survey by measuring CA 125 (twice daily for 5
days) in two human pool sera that were shipped to the
participants in frozen aliquots. The results obtained in the
individual laboratories were compared with the overall
median.
Method comparison studies with the Elecsys assay
were carried out in the participating laboratories with the
Enzymun-Test CA 125 II on ES 300, 600, and 607 enzyme
immunoassays, two microparticle enzyme immunoassays
(MEIA 1 on AxSYM® and MEIA 2 on IMx® immunoana-
lyzers, Abbott Laboratories) and two IRMAs (IRMA 1,
ELSA-CA 125 II; CIS bio international; IRMA 2, Centocor®
CA 125 II; Centocor Inc.). The tests were performed
according to the manufacturers’ protocols. Regression
equations were calculated according to Passing and Bab-
lok (5).
Analytical range. The lower limit of detection was deter-
mined by two different methods. In the one, the calibrator
matrix without antigen was measured in nine indepen-
dent analyses (21 replicates per analysis) in three labora-
tories. The lower limit of detection was defined as the
mean 12 SD of these measurements. In the other, a
human serum sample with a very low CA 125 concentra-
tion was used for the same kind of measurements in one
laboratory. The linearity of the test was analyzed by the
dilution of human pool sera with CA 125 concentrations
up to 4500 kilounits/L with either low-concentration
human pool sera or Elecsys Diluent Universal according
to a recently described protocol (6). The method was
considered linear if the measured concentration deviated
,10% from the expected concentration. The possible
occurrence of a high-dose hook effect was studied by
measuring serial dilutions (with the Elecsys diluent) of
samples with very high concentrations of CA 125.
Interferences. Possible interference by hemolysis, icteria, or
lipemia was analyzed by addition experiments performed
according to a Socie´te´ franc¸aise biologie clinique protocol
(7) as well as by dilution experiments. The effects of
rheumatoid factors, biotin, and dysproteinemia were
checked in the laboratory of the manufacturer. Results
were rated acceptable if the diluted sample or the sample
containing a potentially interfering substance showed a
recovery range of 90–110% of the undiluted sample or the
sample without the interfering substance. Eighteen
widely used drugs and 11 cytotoxic drugs were tested as
described previously (8). The comparability of results
obtained in serum and various types of plasma (heparin,
EDTA, or citrate plasma) derived from the same donors
was studied in four laboratories.
healthy individuals/reference range
Five laboratories participated in the determination of the
reference range, using sera from 593 nonpregnant women
(195 pre- and 293 postmenopausal) and 289 men. Individ-
uals included were .18 years of age and judged appar-
ently healthy by clinical and clinical chemistry parame-
ters. In one laboratory, CA 125 was also measured in sera
derived from 32 women in the first trimester of pregnancy
(weeks 2–9). The results were analyzed by nonparametric
fractile limits, and the 95th percentile was taken as the
upper limit.
benign diseases
Samples from 342 patients with benign diseases were
analyzed. These diseases could be summarized as follows:
80 gynecological diseases (ovarian cysts, ovarian metapla-
sia, endometriosis, uterine leiomyoma, cervicitis, and
squamous metaplasia), 87 liver diseases (cirrhosis, hepa-
titis, necrosis, cysts, cholecystitis, and hemochromatosis),
46 gastrointestinal diseases (acute and chronic pancreati-
tis, colitis ulcerosa, Crohn disease, diverticulosis, and
colon polyps), 33 renal insufficiency patients, and 96 other
benign diseases.
malignancies other than ovarian carcinoma
Sera from 505 patients were included: 56 patients with
endometrial carcinoma, 169 patients with gastrointestinal
carcinoma (colonic, pancreatic, gastric, rectal, or esopha-
geal carcinoma), 58 patients with bronchial carcinoma,
128 patients with breast carcinoma, and 94 patients with
other malignancies (genito-urinary, liver, prostate, hema-
tological, and thyroid).
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ovarian carcinoma patients
Samples drawn at the time of primary diagnosis from 100
patients with ovarian carcinoma were measured [35 stage
I, 17 stage II, 25 stage III, and 11 stage IV according to the
International Federation of Gynecology and Obstetrics
(FIGO) criteria (9)]. The majority of patients had nonmu-
cinous ovarian carcinoma. Additional sera (n 5 171) were
derived from patients during treatment and follow-up.
monitoring of ovarian carcinoma
Measurements with the Elecsys test and IRMA 2 (Cento-
cor CA 125 II; Centocor Inc.) were carried out on samples
obtained serially from 50 clinically well-characterized
patients during treatment and follow-up. Measurements
with Elecsys and Enzymun-Test reagents were performed
in sera collected serially from 10 patients. At least four
points per patient at different monitoring intervals were
tested.
ethics considerations
All procedures followed in this study were in accordance
with the guidelines of the various local ethics committees.
Results and Discussion
analytical performance of the elecsys
ca 125 ii test
Imprecision. In the diagnostically most important range
from 10 to ;100 kilounits/L, within-run CVs of 0.8–3.3%
and between-day CVs of 2.4–10.9% were obtained in
human pool sera (Table 1). Total imprecision CVs ranged
from 2.4% to 7.8%. CVs .10% were found in low-
concentration samples (,13 kilounits/L). There were no
major differences at comparable concentrations in the CVs
for control sera and human sera.
Accuracy. Measurement of CA 125 in two human pool sera
revealed median recoveries of 94–110% for the low-
concentration serum pool (32 kilounits/L) and 86–112%
for the high-concentration serum pool (332 kilounits/L)
by referring the results of the individual laboratories to
the median of all laboratories (data not shown). These
results indicate a good interlaboratory transferability of
the Elecsys CA 125 II test.
The results of the method comparison studies are
summarized in Table 2. Representative examples of
Table 1. Summary of imprecision studies in control serum (CS) and human serum (HS) by ECCLSa protocol.
Imprecision
No. of analyses/
laboratories Material
Concentration,
kilounits/L
CV, %
Min Max Median
Within-run 19/7 CS 1 41.0 0.7 3.3 1.7
19/7 CS 2 126 0.8 2.8 1.5
17/6 HS 1 10.6–22.0 1.0 3.0 2.1
17/5 HS 2 41.1–110 0.8 3.3 1.6
17/5 HS 3 406–1026 1.0 4.8 1.5
Between-day 99/5 CS 1 41.0 2.9 9.0 5.7
98/5 CS 2 126 2.9 7.5 6.2
99/5 HS 1 10.7–21.7 3.0 10.9 10.1
99/4 HS 2 42.0–104 2.4 6.0 4.3
99/4 HS 3 400–1015 5.5 8.8 6.2
a ECCLS, European Committee for Clinical Laboratory Standards.
Table 2. Summary of method comparison studies between Elecsys CA 125 (y) and routine immunochemical methods (x).
Laboratory
no. Method (x)
Range,
kilounits/L
n
Passing/Bablok
regression
Correlation
coefficient syzx, kilounits/LMin Max Slope
Intercept,
kilounits/L
3 EIAa 1 488 286 0.94 2.27 0.987 9.64
4 EIA 1 489 341 0.98 22.84 0.987 12.45
7 EIA 3 457 133 1.07 2.82 0.989 9.14
8 EIA 1 209 136 0.96 1.57 0.932 11.18
4 MEIA 1 3 480 329 1.03 0.81 0.986 13.26
4 MEIA 2 1 405 330 1.23 2.41 0.987 11.67
7 IRMA 1 7 337 96 1.42 26.52 0.977 16.95
1 IRMA 2 1 464 139 0.93 5.57 0.981 9.93
8 IRMA 2 2 240 137 0.89 20.38 0.979 5.06
a EIA, enzyme immunoassay.
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method comparison plots are shown in Fig. 1. The data
presented include only values up to 500 kilounits/L
(measuring range of the comparison methods) to exclude
dilution effects. Similar results were obtained if higher
values were included in the calculation. Although some
outliers were detected, good comparability of the Elecsys
CA 125 II test with Enzymun-Test CA 125 II, MEIA 1, and
IRMA 2 was obtained. Systematic differences were found
in the comparison with MEIA 2 and IRMA 1, which can be
explained by differences in the standardization of these
methods. Comparable systematic deviations between
MEIA 2 and IRMA 2 as well as another CA 125 test were
described in a recent paper (10).
Analytical range. The limit of detection calculated from
repeated measurements of the zero calibrator was found
to be ,0.6 kilounits/L in all analyses. This is equivalent to
the readable limit of the analyzer. One laboratory per-
formed measurements in a serum sample with a CA 125
value of 0.8 kilounits/L. The limit of detection obtained
for serum was 1.1 kilounits/L, which is highly sufficient
for diagnostic purposes.
According to the manufacturer, the assay is linear up to
5000 kilounits/L. This was checked in four laboratories in
a total of 24 dilution series covering three decades of CA
125 concentrations, using either human sera or diluent for
dilution. On the basis of an acceptance range of 90–110%
recovery, the linearity of the assay when serum was used
as diluent was confirmed throughout the range studied
(highest serum concentration ;4500 kilounits/L) with the
exception of the highest dilution, which exceeded the
acceptance criteria in 5 of 12 experiments. The acceptance
criteria were not met with the low-concentration human
pool sera (5–10 kilounits/L) used for dilution. Analytical
Fig. 1. Examples of method comparison studies between the Elecsys CA 125 II and routine immunochemical methods.
(z z z z z), identity lines; (———), Passing-Bablok regressions.
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imprecision at these very low concentrations was a prob-
able cause for this phenomenon. The Elecsys diluent was
found to be suitable provided that the concentration of the
diluted sample was not below ;500 kilounits/L.
No high-dose hook effect was observed up to 26 000
kilounits/L, the highest concentration available. Higher
concentrations can occasionally be encountered in fluids
obtained from ovarian cysts; however, in such cases the
laboratory will already be alerted to the possible presence
of extremely high concentrations by the nature of the
sample. It should be noted that a high-dose hook effect
can occur when samples with extremely high concentra-
tions are measured. Such samples are encountered very
rarely.
Interferences. Addition experiments revealed no effect by
bilirubin up to 850 mmol/L (recovery, 97.2–100.1%), he-
moglobin up to 1.1 mmol/L (recovery, 92.3–101.2%), or
triglycerides up to 10.3 mmol/L (recovery, 100.7–102.7%;
data not shown). The concentrations given are the highest
tested and are representative of interferences encountered
in practice. Comparable results were obtained in dilution
experiments. No influence on the results of the Elecsys CA
125 II test was observed by rheumatoid factor activity
Fig. 2. CA 125 values measured with the Elecsys CA 125 II in patients with benign gynecological diseases and ovarian carcinoma patients
classified according to the FIGO stage.
Fig. 3. CA 125 values measured with the Elecsys CA 125 II in benign and malignant diseases.
1, ovarian cancer; 2, endometrial cancer; 3, mammary cancer; 4, gastrointestinal cancer; 5, bronchial cancer; 6, other cancers; 7, benign liver disease; 8, benign
gastrointestinal disease; 9, renal insufficiency; 10, other benign diseases.
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(1500 kIU/L), biotin (50 mg/L), or in dysproteinemic sera.
The addition of 18 widely used drugs (fivefold therapeu-
tic concentration) and 11 cytotoxic drugs (one-
or fivefold therapeutic concentration) did not affect the
results.
Comparison studies between serum and heparin,
EDTA, and citrate plasma yielded slopes from 0.91 to 1.03,
intercepts ,2.0 kilounits/L, and correlation coefficients of
1.00, thereby indicating that these types of plasma are
suitable as sample material (data not shown).
clinical evaluation
Reference range. CA 125 was measured in 593 apparently
healthy women (pre- and postmenopausal, ages .18
years) in five laboratories. A cutoff value of 35 kilounits/L
(95th percentile) was obtained for the Elecsys CA 125 II
test. This value is identical to the generally accepted cutoff
for other CA 125 assays, which are described in several
publications (11–13). Slightly higher 95th percentile cutoff
CA 125 concentrations were found in premenopausal
women (38 kilounits/L) compared with postmenopausal
women (31 kilounits/L). CA 125 concentrations in women
in the first trimester of pregnancy were frequently .35
kilounits/L (median, 38 kilounits/L), as reported in the
literature (1, 11). A 95th percentile cutoff of 28 kilounits/L
was found in 289 men.
Distribution of CA 125 in Different Groups of Patients. The
distribution of CA 125 values in ovarian carcinoma pa-
tients at the time of primary diagnosis related to the FIGO
stage was compared with that of women suffering from
benign gynecological diseases (Fig. 2). A large overlap
existed in the two groups studied. As shown previously
(11), the magnitude of CA 125 increases was clearly
related to the tumor stage.
CA 125 concentrations in malignancies other than
ovarian carcinoma and various benign diseases are pre-
sented in Fig. 3. As is known, CA 125 is an unspecific
tumor marker [see Ref. (1)]. Although the highest concen-
trations measured with Elecsys CA 125 II were in ovarian
carcinoma patients, very high values frequently occurred
in other malignancies studied. Benign diseases were also
frequently associated with CA 125 values .35 kilo-
units/L. Especially high CA 125 concentrations were
found in the group of benign liver disease patients (95th
percentile, 494 kilounits/L).
Diagnostic Sensitivity and Specificity. For the calculation of
diagnostic sensitivity and specificity, CA 125 values in 100
ovarian carcinoma patients at the time of primary diag-
nosis were compared with 80 patients with benign gyne-
cological diseases (clinically relevant reference group).
The maximum diagnostic efficiency was reached at 150
kilounits/L (specificity, 93%; sensitivity, 69%; Fig. 4).
When specificity was fixed at 95%, following the recom-
mendation of the Hamburg Group for Standardization of
Tumor Markers (14), the sensitivity was 63% (cutoff, 190
kilounits/L). This sensitivity is in agreement with previ-
ously published results for other CA 125 methods, which
described sensitivities from 50% to 60% (10, 15, 16). At the
historical cutoff of 65 kilounits/L (13), the specificity
decreased to 82%.
Apparently healthy women were also used as the
reference group for ovarian carcinoma patients to simu-
late the screening situation. At 35 kilounits/L (95% spec-
Fig. 4. ROC plot for patients with ovarian carcinoma (primary diagnosis,
n 5 100) vs benign gynecological diseases (n 5 80).
Fig. 5. Follow-up of ovarian carcinoma patients, using the Elecsys CA
125 and Enzymun-Test CA 125 (top) or IRMA 2 (bottom).
l, Elecsys CA 125 II; , Enzymun-Test CA 125 II; f, IRMA 2.
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ificity), a sensitivity of 87% was obtained, which confirms
other reports (1, 17) that indicated that measurement of
CA 125 alone has insufficient diagnostic efficiency to be
used as a screening test for the general population [prev-
alence of ovarian cancer, 0.05% (17)] for ovarian cancer. In
this situation the positive predictive value would be only
0.86%.
Follow-up of Ovarian Carcinoma Patients. Representative
examples of the 60 patients studied with the Elecsys CA
125 II and either the Enzymun-Test CA 125 II or IRMA 2
are shown in Fig. 5. When the results obtained by the
different methods were compared, a clear agreement was
found. The CA 125 values were correctly reflecting the
status of the disease and the effect of various therapeutic
measures.
Conclusion
The Elecsys CA 125 II assay has proven to be precise and
accurate. The assay has an extended range (from 0.6 to at
least 4500 kilounits/L) and is free from the interferences
usually encountered. Clinical evaluation showed that the
assay performed very comparably to other established CA
125 II assays. In our view, the Elecsys CA 125 II assay is
suitable for routine use in the diagnosis and follow-up of
ovarian cancer patients.
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